Sense Biodetection Secures Additional $15M in Series B Financing

Sense Biodetection

Sense Biodetection, an Oxford, UK-based up-and-coming diagnostics company focused on the COVID testing landscape, secured an additional $15m in its Series B financing.

The round, which brought the total amount raised to $65m, was led by existing investor Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, Inc.

The company intends to use the funds to support the anticipated U.S. and European commercial launch of its COVID-19 Test on its Veros instrument-free molecular platform. 

Led by Timothy I. Still, CEO, Sense Biodetection is a global molecular diagnostics company focused on bringing lab-quality results through rapid, disposable molecular tests without the constraints of an instrument. The company’s Veros™ product platform aims to enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs.

Sense recently completed an extensive, prospective, multi-site clinical study that supported the company’s Emergency Use Authorization (EUA) submission to the U.S. Food and Drug Administration (FDA) for marketing clearance of the Veros COVID-19 Test.